Evidence map›Paper›PMID 33236012›Full record

ArticlebioRxiv : the preprint server for biology2020

The Development of a Novel Nanobody Therapeutic for SARS-CoV-2.

Gang Ye, Joseph P Gallant, Christopher Massey, Ke Shi, Wanbo Tai, Jian Zheng, Abby E Odle, Molly A Vickers, Jian Shang, Yushun Wan and 9 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 4 institutions in 1 country.

Gang YeDepartment of Veterinary and Biomedical Sciences, University of Minnesota, Saint Paul, MN, USA.
Joseph P GallantDepartment of Pharmacology, University of Minnesota, Minneapolis, MN, USA.
Christopher MasseyInstitutional Office of Regulated Nonclinical Studies, University of Texas Medical Branch, Galveston, TX, USA.
Ke ShiDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, USA.
Wanbo TaiLaboratory of Viral Immunology, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA.
Jian ZhengDepartment of Microbiology and Immunology, University of Iowa, Iowa City, IA, USA.
Abby E OdleDepartment of Microbiology and Immunology, University of Iowa, Iowa City, IA, USA.
Molly A VickersDepartment of Microbiology and Immunology, University of Iowa, Iowa City, IA, USA.
Jian ShangDepartment of Veterinary and Biomedical Sciences, University of Minnesota, Saint Paul, MN, USA.
Yushun WanDepartment of Veterinary and Biomedical Sciences, University of Minnesota, Saint Paul, MN, USA.
Aleksandra DrelichDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Kempaiah R KempaiahDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Vivian TatDepartment of Pathology, University of Texas Medical Branch, Galveston, TX, USA.
Stanley PerlmanDepartment of Microbiology and Immunology, University of Iowa, Iowa City, IA, USA.
Lanying DuLaboratory of Viral Immunology, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA.
Chien-Te TsengDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Hideki AiharaDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, USA.
Aaron M LeBeauDepartment of Pharmacology, University of Minnesota, Minneapolis, MN, USA.
Fang LiDepartment of Veterinary and Biomedical Sciences, University of Minnesota, Saint Paul, MN, USA.
University of Minnesota · USThe University of Texas Medical Branch at Galveston · USUniversity of Iowa · USNew York Blood Center · US

Funding

Structural studies of viral replication and invasionR35GM118047 · NIGMS · UNIVERSITY OF MINNESOTA · PI Hideki Aihara · 2016 to 2026
$6.3M
Receptor recognition mechanisms of coronavirusesR01AI089728 · NIAID · UNIVERSITY OF MINNESOTA · PI Fang Li, Timothy Patrick Sheahan · 2010 to 2026
$4.7M
Novel nanobodies to prevent and treat SARS-CoV-2 and other pathogenic human coronavirusesR01AI157975 · NIAID · NEW YORK BLOOD CENTER · PI DU, LANYING, LI, FANG · 2020 to 2025
$3.9M
NIAID NIH HHS R01 AI089728NIAID NIH HHS R01 AI157975NIGMS NIH HHS R35 GM118047
6 · The paper itself

Abstract

Combating the COVID-19 pandemic requires potent and low-cost therapeutics. We identified a novel series of single-domain antibodies (i.e., nanobody), Nanosota-1, from a camelid nanobody phage display library. Structural data showed that IMPACT STATEMENT: Potent and low-cost

Identifiers

PMID33236012
PMCPMC7685322
OpenAlexW3102241621

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.